Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology · 10.03.2023 · 41 (8) · 1590-1599
DOI: 10.1200/jco.22.00940 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2023. Verfasst von Meletios A Dimopoulos und 21 weiteren Autor:innen. Beteiligte Einrichtung: National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 146-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the time of final analysis for overall survival (OS). METHODS POLLUX was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned 1:1 to D-Rd or Rd until disease progression or unacceptable toxicity. After positive primary analysis and protocol amendment, patients receiving Rd were offered daratumumab monotherapy after disease progression. RESULTS Significant OS benefit was observed with D-Rd (hazard ratio, 0.73; 95% CI, 0.58 to 0.91; P = .0044) at a median (range) follow-up of 79.7 months (0.0-86.5). The median OS was 67.6 months for D-Rd compared with 51.8 months for Rd. Prespecified analyses demonstrated an improved OS with D-Rd versus Rd in most subgroups, including patients age ≥ 65 years and patients with one, two, or three prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and refractoriness to their last prior line of therapy or a proteasome inhibitor. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Rd versus Rd were neutropenia (57.6% v 41.6%), anemia (19.8% v 22.4%), pneumonia (17.3% v 11.0%), thrombocytopenia (15.5% v 15.7%), and diarrhea (10.2% v 3.9%). CONCLUSION D-Rd significantly extended OS versus Rd alone in patients with RRMM. To our knowledge, for the first time, our findings, together with the OS benefit observed with daratumumab plus bortezomib and dexamethasone in the phase III CASTOR trial, demonstrate OS improvement with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02076009 [POLLUX]).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National and Kapodistrian University of Athens, Athens, Greece.
- Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
- Division of Hematology, Department of Medicine, Karolinska Institute, Karolinska University Hospital at Huddinge, Stockholm, Sweden.
- Clínica Universidad de Navarra, CCUN, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
- Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
- Memorial Sloan Kettering Cancer Center, New York, NY.
ORCID-Profile: Meletios A Dimopoulos, Albert Oriol, Jesus San-Miguel, Nizar J Bahlis, Saad Z Usmani, Robert Z Orlowski, Sung-Soo Yoon, Paul G Richardson, Hartmut Goldschmidt, Xue Gai, Philippe Moreau
Förderung
- NCI NIH HHS
Zitieren
APA
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Suzuki, K., Plesner, T., Yoon, S. S., Ben Yehuda, D., Richardson, P. G., Goldschmidt, H., Reece, D., Ahmadi, T., Qin, X., Garvin Mayo, W., Gai, X., …, & Moreau, P. (2023). Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology, 41(8), 1590-1599. https://doi.org/10.1200/jco.22.00940
Vancouver
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. 2023;41(8):1590-1599. doi:10.1200/jco.22.00940
BibTeX
@article{Dimopoulos2023,
author = {Dimopoulos, Meletios A and Oriol, Albert and Nahi, Hareth and San-Miguel, Jesus and Bahlis, Nizar J and Usmani, Saad Z and Rabin, Neil and Orlowski, Robert Z and Suzuki, Kenshi and Plesner, Torben and Yoon, Sung-Soo and Ben Yehuda, Dina and Richardson, Paul G and Goldschmidt, Hartmut and Reece, Donna and Ahmadi, Tahamtan and Qin, Xiang and Garvin Mayo, Wendy and Gai, Xue and Carey, Jodi and Carson, Robin and Moreau, Philippe},
title = {Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {8},
pages = {1590--1599},
doi = {10.1200/jco.22.00940}
}
EUVIMED